The cost of living crisis: Have markets over-rated the impact it will have on stocks?
Cost of living crisis? What Cost of living crisis? For the last year, interest rates and inflation have increased at…
Its FY23 results reporting season for some companies – these 3 reported strong profits this morning
It is FY23 reporting season for ASX-companies that use April 1-March 31 as their financial year. This is mostly New…
This ASX pharmaceutical company is paying its first dividend, over 25 years since its founding
ASX pharmaceutical company AFT Pharmaceuticals (ASX:AFP) is paying investors a dividend for the first time since it was founded in…
ASX travel shares: Here’s why investors should be on high-alert
Yesterday Alloggio (ASX:ALO) had bad news for shareholders and we think investors in other ASX travel shares should be wary…
It’s reporting season for ASX New Zealand companies! But which stock will be the most interesting to watch?
ASX New Zealand companies are amidst reporting season right now. Although most companies use either the calendar year or July…
Lefroy Exploration reckons it has over 600,000oz of gold, but investors are not buying it
Lefroy Exploration (ASX:LEX) has unveiled its maiden Mineral Resource Estimate (MRE) for its Burns Deposit. It has 602,302/oz gold and…
Tyro Payments upgrades its FY23 guidance, so why the muted response from shareholders?
Tyro Payments (ASX:TYR) delivered some good news for shareholders this morning, in the form of upgraded FY23 guidance. But the shareholder…
Lithium stocks are on fire. Should you get in now?
Lithium stocks are on fire! Getting ready for the flood. Major miners are eyeing Australia’s lithium stocks as big money…
NextDC (ASX:NXT) upgrades its guidance and unveils a $618m capital raising
NextDC (ASX:NXT), the ASX’s biggest data centre operator that was funded by Bevan Slattery, is undertaking its first capital raising…
This ASX sector is the biggest 2023-24 budget winner
Which ASX sector is the biggest budget winner? In our view, it is the built-to-rent sector. No time to…
Investors in Cyclopharm shares (ASX:CYC) just received some welcome clarity on the FDA approval process
Cyclopharm shares (ASX:CYC) are hinging on the fate of whether or not the company is able to obtain FDA approval…
Tower slashes its FY23 NPAT guidance
Tower (ASX:TWR) is another insurer that has been feeling the pinch from catastrophic weather events. The company has been hit…
How are lending stocks holding up as interest rates rise as fast as they have?
Just how would Lending stocks would perform amidst higher interest rates? Theoretically they would do better, but that is not…
Meet Embark Education (ASX:EVO), the latest Kiwi company to take the famous ‘Xero route’
Embark Education (ASX:EVO), once known as Evolve Education, is taking a path once trod by Xero. The company was dual-listed…
ASX Life Sciences stocks: Mr. Biotech thinks that 2023 could be a very good year to buy them
ASX Life Sciences stocks are back, baby! ASX Life Science stocks have suffered heavily in 2022 due to investors shifting…